Elizabeth Selvin1, Andreea M Rawlings2, Morgan Grams3, Ronald Klein4, A Richey Sharrett5, Michael Steffes6, Josef Coresh2. 1. Department of Epidemiology and the Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; Division of General Internal Medicine, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA. Electronic address: lselvin@jhsph.edu. 2. Department of Epidemiology and the Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; Division of General Internal Medicine, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA. 3. Division of Nephrology, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA. 4. Department of Ophthalmology and Visual Sciences, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. 5. Department of Epidemiology and the Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 6. Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MD, USA.
Abstract
BACKGROUND: HbA1c is the standard measure by which to monitor long-term (2-3 months) glucose control in people with diabetes and is now used for diagnosis of diabetes. Fructosamine and glycated albumin are markers of short-term (2-4 weeks) glycaemic control that might add complementary prognostic information to HbA1c. Our aim was to clarify the performance of fructosamine and glycated albumin measurements for identifying people at risk of incident diabetes or diabetic complications. METHODS: We measured glycated albumin and fructosamine in blood samples from 11 348 adults without diabetes and 958 adults diagnosed with diabetes mellitus (both type 1 and 2) who attended the second examination of the Atherosclerosis Risk in Communities (ARIC) study in 1990-92 (baseline). We assessed the associations of fructosamine and glycated albumin with risk of incident diabetes, retinopathy, and risk of incident chronic kidney disease (CKD), during two decades of follow-up. We compared these associations with those of HbA1c with incident diabetes, retinopathy, and CKD. For analyses of associations with incident diabetes and CKD, adjusted hazard ratios (HRs) and their corresponding 95% CIs were estimated using Cox proportional hazards models. Model discrimination was assessed using Harrell's C statistic. FINDINGS: The HRs for incident diabetes were 4·96 (4·36-5·64) for fructosamine above the 95th percentile and 6·17 (5·45-6·99) for glycated albumin above the 95th percentile. Associations were attenuated but persisted after adjustment for HbA1c. Fructosamine and glycated albumin were strongly associated with retinopathy (p<0·0001 for trend). The multivariable-adjusted HRs for CKD for people with fructosamine and glycated albumin above the 95th percentile were 1·50 (95% CI 1·22-1·85) and 1·48 (1·20-1·83), respectively, when compared with people with no diabetes and fructosamine or glycated albumin below the 75th percentile. Prediction of incident CKD by fructosamine (C statistic 0·717) and glycated albumin (0·717) were nearly as strong as by HbA1c (0·726), but HbA1c outperformed fructosamine and glycated albumin for prediction of incident diabetes with C statistics of 0·760, 0·706, and 0·703, respectively. INTERPRETATION: Fructosamine and glycated albumin were strongly associated with incident diabetes and its microvascular complications, with prognostic value comparable to HbA1c. FUNDING: National Heart, Lung, and Blood Institute.
BACKGROUND: HbA1c is the standard measure by which to monitor long-term (2-3 months) glucose control in people with diabetes and is now used for diagnosis of diabetes. Fructosamine and glycated albumin are markers of short-term (2-4 weeks) glycaemic control that might add complementary prognostic information to HbA1c. Our aim was to clarify the performance of fructosamine and glycated albumin measurements for identifying people at risk of incident diabetes or diabetic complications. METHODS: We measured glycated albumin and fructosamine in blood samples from 11 348 adults without diabetes and 958 adults diagnosed with diabetes mellitus (both type 1 and 2) who attended the second examination of the Atherosclerosis Risk in Communities (ARIC) study in 1990-92 (baseline). We assessed the associations of fructosamine and glycated albumin with risk of incident diabetes, retinopathy, and risk of incident chronic kidney disease (CKD), during two decades of follow-up. We compared these associations with those of HbA1c with incident diabetes, retinopathy, and CKD. For analyses of associations with incident diabetes and CKD, adjusted hazard ratios (HRs) and their corresponding 95% CIs were estimated using Cox proportional hazards models. Model discrimination was assessed using Harrell's C statistic. FINDINGS: The HRs for incident diabetes were 4·96 (4·36-5·64) for fructosamine above the 95th percentile and 6·17 (5·45-6·99) for glycated albumin above the 95th percentile. Associations were attenuated but persisted after adjustment for HbA1c. Fructosamine and glycated albumin were strongly associated with retinopathy (p<0·0001 for trend). The multivariable-adjusted HRs for CKD for people with fructosamine and glycated albumin above the 95th percentile were 1·50 (95% CI 1·22-1·85) and 1·48 (1·20-1·83), respectively, when compared with people with no diabetes and fructosamine or glycated albumin below the 75th percentile. Prediction of incident CKD by fructosamine (C statistic 0·717) and glycated albumin (0·717) were nearly as strong as by HbA1c (0·726), but HbA1c outperformed fructosamine and glycated albumin for prediction of incident diabetes with C statistics of 0·760, 0·706, and 0·703, respectively. INTERPRETATION:Fructosamine and glycated albumin were strongly associated with incident diabetes and its microvascular complications, with prognostic value comparable to HbA1c. FUNDING: National Heart, Lung, and Blood Institute.
Authors: M M Engelgau; T J Thompson; W H Herman; J P Boyle; R E Aubert; S J Kenny; A Badran; E S Sous; M A Ali Journal: Diabetes Care Date: 1997-05 Impact factor: 19.112
Authors: Barry I Freedman; Rajeev N Shenoy; Jonathan A Planer; Kimberly D Clay; Zak K Shihabi; John M Burkart; Cesar Y Cardona; Lilian Andries; Todd P Peacock; Hernan Sabio; Joyce R Byers; Gregory B Russell; Anthony J Bleyer Journal: Perit Dial Int Date: 2010 Jan-Feb Impact factor: 1.756
Authors: Bruce B Duncan; Maria Inês Schmidt; James S Pankow; Christie M Ballantyne; David Couper; Alvaro Vigo; Ron Hoogeveen; Aaron R Folsom; Gerardo Heiss Journal: Diabetes Date: 2003-07 Impact factor: 9.461
Authors: Tien Y Wong; Gerald Liew; Robyn J Tapp; Maria Inês Schmidt; Jie Jin Wang; Paul Mitchell; Ronald Klein; Barbara E K Klein; Paul Zimmet; Jonathan Shaw Journal: Lancet Date: 2008-03-01 Impact factor: 79.321
Authors: Elizabeth Selvin; Lesley M A Francis; Christie M Ballantyne; Ron C Hoogeveen; Josef Coresh; Frederick L Brancati; Michael W Steffes Journal: Diabetes Care Date: 2011-02-18 Impact factor: 19.112
Authors: Michael Bergman; Muhammad Abdul-Ghani; João Sérgio Neves; Mariana P Monteiro; Jose Luiz Medina; Brenda Dorcely; Martin Buysschaert Journal: J Clin Endocrinol Metab Date: 2020-08-01 Impact factor: 5.958
Authors: Anne E Sumner; Michelle T Duong; Paola C Aldana; Madia Ricks; Marshall K Tulloch-Reid; Jay N Lozier; Stephanie T Chung; David B Sacks Journal: Diabetes Care Date: 2015-12-17 Impact factor: 19.112
Authors: Christina M Parrinello; A Richey Sharrett; Nisa M Maruthur; Richard M Bergenstal; Morgan E Grams; Josef Coresh; Elizabeth Selvin Journal: Diabetes Care Date: 2015-12-17 Impact factor: 19.112
Authors: Ning Ding; Lucia Kwak; Shoshana H Ballew; Bernard Jaar; Ron C Hoogeveen; Christie M Ballantyne; A Richey Sharrett; Aaron R Folsom; Gerardo Heiss; Maya Salameh; Josef Coresh; Alan T Hirsch; Elizabeth Selvin; Kunihiro Matsushita Journal: Atherosclerosis Date: 2018-04-30 Impact factor: 5.162